01/21/21 8:30 AMNASDAQ : JAGXJaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company's Anticipated Subsidiary in ItalyJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")RHEA-AIneutral
01/20/21 8:30 AMNASDAQ : JAGXJaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review VoucherJaguar Health, Inc. (NASDAQ:JAGX)RHEA-AIneutral
01/15/21 8:30 AMNASDAQ : JAGXJaguar Health Provides Replay Link & High-level Overview of January 14th Investor WebcastJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from theRHEA-AIneutral
01/13/21 8:00 AMNASDAQ : JAGXJaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq RulesJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870RHEA-AIneutral
01/13/21 8:00 AMNASDAQ : JAGXJaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review VoucherThis additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. WebcastRHEA-AIneutral
01/12/21 8:30 AMNASDAQ : JAGXJaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual ConferenceJaguar Health, Inc. (NASDAQ:JAGX)RHEA-AIneutral
01/11/21 8:30 AMNASDAQ : JAGXJaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in 'Long-Hauler' COVID-19 Recovery Patients in EuropeJaguar Health, Inc.RHEA-AIneutral
01/06/21 8:30 AMNASDAQ : JAGXJaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from CholeraJaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today, January 6,RHEA-AIneutral
12/23/20 8:30 AMNASDAQ : JAGXJaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue StreamNo royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi (R)) for cancer therapy-related diarrhea (CTD), for whichRHEA-AIvery positive
12/22/20 12:00 PMNASDAQ : JAGXJaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor WebinarAll proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of new coronavirus strain underscoring urgency to seek European conditional approval for crofelemer forRHEA-AIneutral
